Drug Profile
Zoledronic acid - Sagent Pharmaceuticals
Latest Information Update: 20 Oct 2021
Price :
$50
*
At a glance
- Originator Allergan
- Developer Sagent Pharmaceuticals
- Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
- Mechanism of Action Bone resorption factor inhibitors; Geranylgeranyltransferase inhibitors; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bone metastases; Malignant hypercalcaemia; Multiple myeloma; Prostate cancer
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie